Kiora Pharmaceuticals Inc. (KPRX)

$3.01 -0.01 (-0.33%)
Market Cap 9.19M
Revenue (ttm) 16.02M
Net Income (ttm) 3.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 22.41%
Debt to Equity Ratio 0.00
Volume 28,200
Avg Vol 536,658
Day's Range N/A - N/A
Shares Out 3.04M
Stochastic %K 23%
Beta -0.68
Analysts Strong Sell
Price Target $11.00

Company Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 224 9600
Address:
332 Encinitas Boulevard, Suite 102, Encinitas, United States
Pumpb0t
Pumpb0t Jun. 17 at 12:53 AM
$MULN $KPRX sentiment at 42
0 · Reply
Pumpb0t
Pumpb0t Jun. 17 at 12:18 AM
$MULN $SCNI $BANL $KPRX ready to sploosh me thinks
0 · Reply
Pumpb0t
Pumpb0t Jun. 16 at 8:52 PM
$MULN $SCNI $BANL $KPRX $SOAR sleeping squeezers
0 · Reply
Pumpb0t
Pumpb0t Jun. 15 at 10:57 PM
$MULN $SCNI $BANL $KPRX
0 · Reply
Alright_x3
Alright_x3 Jun. 12 at 11:56 AM
$KPRX
0 · Reply
Jake140
Jake140 Jun. 12 at 11:35 AM
$KPRX
0 · Reply
Eliza1
Eliza1 Jun. 11 at 11:50 PM
$KPRX i put a sell order for over $8-and will just forget about it until it happens, which it will. No sellers-eventually, the shorts will cover and more good news will come out.
0 · Reply
Jake140
Jake140 Jun. 11 at 7:39 AM
$KPRX
0 · Reply
Pumpb0t
Pumpb0t Jun. 11 at 2:03 AM
$KPRX on its way back to $7.67
0 · Reply
GabeOwners
GabeOwners Jun. 10 at 5:18 PM
$KPRX trying to break out
0 · Reply
Latest News on KPRX
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Jun 3, 2025, 7:00 AM EDT - 13 days ago

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

May 9, 2025, 7:00 AM EDT - 5 weeks ago

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 7:00 AM EDT - 2 months ago

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Mar 25, 2025, 7:00 AM EDT - 2 months ago

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Mar 12, 2025, 7:00 AM EDT - 3 months ago

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Feb 13, 2025, 7:00 AM EST - 4 months ago

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Feb 11, 2025, 6:45 AM EST - 4 months ago

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Nov 8, 2024, 7:00 AM EST - 7 months ago

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Oct 29, 2024, 6:45 AM EDT - 8 months ago

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 25, 2024, 9:55 AM EDT - 9 months ago

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Bonds still bouncing along

Sep 9, 2024, 4:55 PM EDT - 10 months ago

Bonds still bouncing along

CPLS EYEG HYFI JPST TLT USHY YEAR

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Aug 9, 2024, 7:00 AM EDT - 11 months ago

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Jul 30, 2024, 6:45 AM EDT - 11 months ago

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Jul 10, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

DARE

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Jun 25, 2024, 6:45 AM EDT - 1 year ago

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

May 10, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

May 6, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Mar 28, 2024, 6:45 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Mar 8, 2024, 7:00 AM EST - 1 year ago

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Jan 31, 2024, 6:40 PM EST - 1 year ago

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini

Jan 31, 2024, 5:15 PM EST - 1 year ago

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini

AllianceBernstein Launches Five New Active ETFs

Dec 13, 2023, 7:30 AM EST - 1 year ago

AllianceBernstein Launches Five New Active ETFs

AB BUFC CPLS EYEG TAFL TAFM

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Nov 9, 2023, 7:18 AM EST - 1 year ago

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Nov 4, 2023, 12:15 PM EDT - 1 year ago

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Oct 3, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Sep 21, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Sep 18, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Sep 14, 2023, 7:01 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Sep 1, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Aug 29, 2023, 1:43 PM EDT - 1 year ago

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Aug 23, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Aug 22, 2023, 1:06 PM EDT - 1 year ago

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Aug 16, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease

Jul 5, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease

Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

Jun 15, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering

Jun 2, 2023, 8:30 AM EDT - 2 years ago

Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering

Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments

May 9, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments

Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting

May 1, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting

Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind

Apr 27, 2023, 2:55 PM EDT - 2 years ago

Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind

Pumpb0t
Pumpb0t Jun. 17 at 12:53 AM
$MULN $KPRX sentiment at 42
0 · Reply
Pumpb0t
Pumpb0t Jun. 17 at 12:18 AM
$MULN $SCNI $BANL $KPRX ready to sploosh me thinks
0 · Reply
Pumpb0t
Pumpb0t Jun. 16 at 8:52 PM
$MULN $SCNI $BANL $KPRX $SOAR sleeping squeezers
0 · Reply
Pumpb0t
Pumpb0t Jun. 15 at 10:57 PM
$MULN $SCNI $BANL $KPRX
0 · Reply
Alright_x3
Alright_x3 Jun. 12 at 11:56 AM
$KPRX
0 · Reply
Jake140
Jake140 Jun. 12 at 11:35 AM
$KPRX
0 · Reply
Eliza1
Eliza1 Jun. 11 at 11:50 PM
$KPRX i put a sell order for over $8-and will just forget about it until it happens, which it will. No sellers-eventually, the shorts will cover and more good news will come out.
0 · Reply
Jake140
Jake140 Jun. 11 at 7:39 AM
$KPRX
0 · Reply
Pumpb0t
Pumpb0t Jun. 11 at 2:03 AM
$KPRX on its way back to $7.67
0 · Reply
GabeOwners
GabeOwners Jun. 10 at 5:18 PM
$KPRX trying to break out
0 · Reply
Alright_x3
Alright_x3 Jun. 10 at 1:10 PM
$KPRX
0 · Reply
Jake140
Jake140 Jun. 10 at 10:33 AM
$KPRX
0 · Reply
GabeOwners
GabeOwners Jun. 10 at 7:29 AM
$KPRX probably worth around $10
0 · Reply
tradinghunting
tradinghunting Jun. 9 at 8:32 PM
$KPRX 4+
0 · Reply
Eliza1
Eliza1 Jun. 9 at 7:44 PM
$KPRX $KLTO up 9xs with news that is equal to KPRX's news last week, yet they only rise 1.5 xs-it really is time to move KPRX over $10 at least.
1 · Reply
Jake140
Jake140 Jun. 9 at 9:07 AM
$KPRX
0 · Reply
Eliza1
Eliza1 Jun. 6 at 10:06 PM
$KPRX it needs a good squeeze like $MODV and $EYEN , probably Monday
0 · Reply
Jake140
Jake140 Jun. 6 at 8:54 PM
$KPRX
0 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Jun. 6 at 5:14 PM
🔥 Weekly Recap: Top 5 Trade Alerts 🔥 1️⃣ $INM 🚀 +186.93% 🔹 Entry: 3.29 → High: 9.44 2️⃣ $KPRX 🚀 +87.32% 🔹 Entry: 4.10 → High: 7.68 3️⃣ $RSLS 🚀 +54.03% 🔹 Entry: 6.20 → High: 9.55 4️⃣ $ZENA 🚀 +52.76% 🔹 Entry: 4.53 → High: 6.92 5️⃣ $EHGO 🚀 +34.29% 🔹 Entry: 1.40 → High: 1.88 📊 Weekly Stats ✅ 36W / 1L 🚀 Gain Potential: +1,028% 📊 2025 YTD 🏆 558W / 36L 🚀 Gain Potential: +24,934% ✨ Avg Gain/Winning Alert: 44.68%
1 · Reply
Jake140
Jake140 Jun. 6 at 11:11 AM
$KPRX Big fan here...holding steady.
0 · Reply
Pegy
Pegy Jun. 5 at 3:41 PM
$KPRX
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 5 at 3:17 PM
$KPRX has soared 11% higher to 2% (~162Kv) in the last few minutes, follow for more volatility.
0 · Reply